CME online

in association with the 21th Annual World Congress on Insulin Resistance
Diabetes and Cardiovascular Disease -WCIRDC

Winning the Trifecta of Diabetes, Heart Disease and Kidney Disease

This is a CME Symposium Supported by an Educational Grant from AstraZeneca
Provided By:

Administrated by::
This CME online educational activity is approved for a maximum of 1.75 AMA PRA Category 2 Credit(s). and ABIM MOC

Accreditation period: January 15, 2023– January 15, 2024

To get started:

Login / Register
CME information
View Agenda
Course presentation

To Receive a Certificate for This CME Activity:  

View the presentations in this CME activity and complete the evaluation. Your certificate will be mailed to you upon satisfactory completion of these documents.

Winning the Trifecta of Diabetes, Heart Disease and Kidney Disease
Agenda

Introduction & Pre-CME Questions
Muthiah Vaduganathan, MD, MPH

Early intervention in Diabetes addressing pathophysiology in preventing comorbidities
Vivian A. Fonseca, MD

SGLT2i effects across the spectrum of CKD and multiple Populations
Peter Rossing, MD

Impact of SGLT2i on HF Outcomes in Various Populations & the range of LVEF
Muthiah Vaduganathan, MD, MPH

Panel Discussion and Q&A:
Changing the Trajectory of Heart Failure and CKD, Implementing Guidelines Directed Medical Therapy
Case Presentation:
Yehuda Handelsman, MD
Panel:
Vivian A. Fonseca, MD · Christian W. Mende, MD Erin D. Michos, MD · Peter Rossing, MD · Muthiah Vaduganathan, MD
Moderator: Yehuda Handelsman, MD

Faculty

Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE, Chair

Medical Director & Principal Investigator
The Metabolic Institute of America
Chair & Program Director
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) / Heart in Diabetes (HID)
Chair & Founder
International Committee for Insulin Resistance
Tarzana, California

Muthiah Vaduganathan, MD, MPH, FACC, FHFA, Chair

Cardiologist and Clinical Trialist
Brigham and Women’s Hospital and
Harvard Medical School
Co-director, Center for Cardiometabolic
Implementation Science
Boston, Massachusetts

Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Medical Center
New Orleans, Louisiana

Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC

Director of Women Cardiovascular Health Research
Associate Director of Preventive Cardiology
Division of Cardiology
Johns Hopkins University School of Medicine
Co-Director, IMPACT Center at JHU
Co-Editor in Chief
American Journal of Preventive Cardiology
Baltimore, Maryland

Peter Rossing, MD, DMSc

Professor, Department of Clinical Medicine
University of Copenhagen
Steno Diabetes Center Copenhagen
Herlev, Denmark

Christian W. Mende, MD, FACP, FACN, FASN, FAHA

Clinical Professor of Medicine
University of California San Diego
La Jolla, California

Program Description

This satellite symposium will explore the changing landscape of therapies for the trifecta of diabetes, HF, and CKD. The program will address gaps in physicians’ knowledge of the interconnections between diabetes, CKD, and heart failure and how to comprehensively manage these conditions when anyone, two, or all three are present in the same patient. The program will also address the management of patients with heart failure and CKD with no diabetes.




Learning Objectives

Upon completion of this CME symposium, participants should be able to:

  • Understand the impact of early therapeutic interventions on the pathophysiologic pathways underlying the development of CKD and HF in patients with diabetes.
  • Review evidence supporting the use of SGLT2 inhibitors across a wide range of patient populations with CKD.
  • Describe Guidelines directed to medical therapy for patients with heart failure.
  • Implement medical therapy regimens for patients with comorbid diseases, including those with HF and CKD, with and without diabetes.

    • Target Audience

    This educational initiative is designed for cardiologists, endocrinologists, nephrologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of people with Heart failure or Type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.

    CME Statement

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PES Inc. is accredited by the ACCME to provide continuing medical education for physicians.

    PESI, Inc, designated this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.